The aim of the present investigation was twofold: to determine the occurrence of sensory neuropathy in the bone marrow in a mouse model of type 1 diabetes (early stage) and to verify whether systemic NGF gene therapy can prevent such a bone marrow pathology and the consequent defect in progenitor cell mobilisation following limb ischaemia. The gene discussed is NGF; the disease is type 1 diabetes mellitus.